2,5-dioxopyrrolidin-1-yl 2-([1,1'-biphenyl]-4-yl)acetate | 141537-22-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,5-dioxopyrrolidin-1-yl 2-([1,1'-biphenyl]-4-yl)acetate
• 英文别名: (2,5-dioxopyrrolidin-1-yl) 2-(4-phenylphenyl)acetate
• CAS: 141537-22-6
• 化学式: C₁₈H₁₅NO₄
• 分子量: 309.321
• InChiKey: HUSRUXIRBDECOG-UHFFFAOYSA-N

物化性质

• 沸点：
  479.8±48.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  63.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,5-dioxopyrrolidin-1-yl 2-([1,1'-biphenyl]-4-yl)acetate 在 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 为溶剂， 生成
  参考文献：
  名称：

  Structure–activity relationships of neuropeptide Y Y1 receptor antagonists related to BIBP 3226

  摘要：

  Analogues of BIBP 3226, (R)-N-alpha-diphenylacetyl-N-(4-hydroxybenzyl)argininamide, were synthesized and investigated for Y-1 antagonism (Ca2+-assay, HEL cells) and binding on Y-1, Y-2 and Y-5 receptors. Replacing the benzylamino by a tetrahydrobenzazepinyl group preserves most of the Y-1 activity. Combination with a N-G-phenylpropyl arginine and a N-alpha-p-biphenyly-lacetyl moiety shifted the NPY receptor selectivity towards Y-5 (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00292-4
• 作为产物：
  描述：

  N-羟基丁二酰亚胺 、 4-联苯乙酸 在 N,N'-二环己基碳二亚胺 作用下， 以 1,4-二氧六环 为溶剂， 以71%的产率得到2,5-dioxopyrrolidin-1-yl 2-([1,1'-biphenyl]-4-yl)acetate
  参考文献：
  名称：

  PCR掺入了具有不同亲水性的芳烃取代基修饰的dUMP：C5修饰的dUTP的合成，以及使用Taq，Tth，Vent（exo-）和Deep Vent（exo-）聚合酶进行PCR研究。

  摘要：

  已经合成了在嘧啶环的C5位被具有不同亲水性的各种芳烃取代基修饰的脱氧尿苷三磷酸衍生物（dUTP）。芳族烃取代基通过CHCHCH2NHCOCH2连接基连接到dUTP。研究了使用Taq，Tth，Vent（exo-）和Deep Vent（exo-）聚合酶以及在该序列中三个不同位点包含一个，两个和三个相邻腺嘌呤核苷酸的模型DNA模板进行PCR掺入修饰的dUMP的效率。对于所有使用的聚合酶，修饰的PCR产物的产率随着芳烃取代基亲水性的增加而显着提高。特别是对于上述聚合酶，被研究的亲水性最强的芳烃取代基（4-羟基苯基残基）改性的dUMP的掺入效率为dTMP掺入效率的60-85％。同时，被2-，4-甲氧基苯基，苯基和4-硝基苯基取代基修饰的dUMP的掺入相对效率为20％至50％，对于1-萘和4-联苯基为2-18％ ，是所研究的芳烃取代基中疏水性最高的。

  DOI：

  10.1016/j.bioorg.2020.103829

文献信息

• Sialic acid dimers
  申请人：Brossmer Reinhard

  公开号：US09260467B2

  公开（公告）日：2016-02-16

  Sialic acid derivatives of the formula (I) in which the symbols have the definitions stated in the description are suitable as medicaments, more particularly for diseases whose course is influenced by Siglec ligands.

  公式（I）中的唾液酸衍生物 其中符号的定义如描述中所述，适用作为药物，更具体地用于受Siglec配体影响的疾病。
• In-vitro Evaluation of Biphenylyl Acetic Acid-β-Cyclodextrin Conjugates as Colon-targeting Prodrugs: Drug Release Behaviour in Rat Biological Media
  作者：Fumitoshi Hirayama、Kunihiro Minami、Kaneto Uekama

  DOI：10.1111/j.2042-7158.1996.tb05871.x

  日期：2011.4.12

  Biphenylyl acetic acid was selectively conjugated to one of the primary hydroxyl groups of β-cyclodextrin through an ester- or amide-linkage, and the physicochemical properties (aqueous solubility and hydrolysis) were investigated.

  Aqueous solubility of the conjugates was lower than those of either drug or parent β-cyclodextrin. The amide conjugate was stable in aqueous solution and in rat biological fluids and gastrointestinal contents. The ester conjugate was hydrolysed to β-cyclodextrin and biphenylyl acetic acid at moderate rates resulting in a V-shaped rate-pH profile in aqueous solution. The ester conjugate released the drug preferentially when incubated with the contents of caecum or colon, whereas no appreciable drug release was observed on incubation with contents of stomach or intestine, nor on incubation with intestinal or liver homogenates, nor on incubation with rat blood.

  The present results suggest that the ester-type drug conjugate of β-cyclodextrin may serve as a colon-targeting prodrug.

  苯基乙酸通过酯或酰胺键与β-环糊精的一个原始羟基选择性结合，研究了其物理化学性质（水溶性和水解）。

  这些结合物的水溶性低于药物或原始的β-环糊精。酰胺结合物在水溶液和大鼠生物液和胃肠内容物中稳定。酯结合物在水溶液中呈V形速率-pH曲线，以适度的速率水解为β-环糊精和苯基乙酸。当与盲肠或结肠的内容物孵育时，酯结合物优先释放药物，而在胃或肠的内容物孵育，肠或肝脏匀浆孵育以及大鼠血液孵育中均未观察到明显的药物释放。

  这些结果表明，β-环糊精的酯型药物结合物可能作为结肠靶向前药。

• Cyclic polypeptide with antibiotic activity and a process for preparation thereof
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0729974A1

  公开（公告）日：1996-09-04

  A polypeptide compound of the following general formula : whereinR1 is acyl group, R2 is acyloxy, R3 is hydrogen and R4 is hydrogen and a pharmaceutically acceptable salt thereof, a process for its preparation and pharmaceutical compositions comprising it. The invention relates also to use of the compound for the manufacture of a medicament for treating or preventing infectious diseases.

  以下是通用式的多肽化合物： 其中，R1是酰基，R2是酰氧基，R3是氢，R4是氢，以及其药学上可接受的盐，制备该化合物的方法以及包含它的制药组合物。本发明还涉及使用该化合物制造治疗或预防传染病的药物。
• RAPID GLYCOPEPTIDE OPTIMIZATION VIA NEOGLYCOSYLATION
  申请人：Thorson Jon S.

  公开号：US20080114157A1

  公开（公告）日：2008-05-15

  The present invention generally relates to methods and compositions for generating vancomycin analogs. Specifically the invention relates to generating a vancomycin library through chemoselective ligation of a sugar moiety with a vancomycin aglycon. In particular, the present invention provides a library of vancomycin analogs, where the member of the library comprises at least one vancomycin analog selected from 2′-N-acyldecanoyl-glucosyl vancomycin neoglycoside, 3′-N-acyldecanoyl-glucosyl vancomycin neoglycoside, 4′-N-acyldecanoyl-glucosyl vancomycin neoglycoside, 6′-N-acyldecanoyl-glucosyl vancomycin neoglycoside, 2′-N-acylbiphenyl-glucosyl vancomycin neoglycoside, 3′-N-acylbiphenoyl-glucosyl vancomycin neoglycoside, 4′-N-acylbiphenoyl-glucosyl vancomycin neoglycoside and 6′-N-acylbiphenoyl-glucosyl vancomycin neoglycoside.

  本发明一般涉及用于生成万古霉素类似物的方法和组合物。具体而言，本发明涉及通过糖基与万古霉素非糖基的化学选择性连接来生成万古霉素文库。特别地，本发明提供了一个万古霉素类似物文库，其中该文库的成员包括至少一种从2'-N-酰基癸酰基-葡萄糖基万古霉素新糖苷、3'-N-酰基癸酰基-葡萄糖基万古霉素新糖苷、4'-N-酰基癸酰基-葡萄糖基万古霉素新糖苷、6'-N-酰基癸酰基-葡萄糖基万古霉素新糖苷、2'-N-酰基联苯基-葡萄糖基万古霉素新糖苷、3'-N-酰基联苯基-葡萄糖基万古霉素新糖苷、4'-N-酰基联苯基-葡萄糖基万古霉素新糖苷和6'-N-酰基联苯基-葡萄糖基万古霉素新糖苷中选择的至少一种万古霉素类似物。
• [EN] HYPOIMMUNOGENIC BIOTHERAPEUTICS<br/>[FR] BIOTHÉRAPEUTIQUES HYPOIMMUNOGÈNES
  申请人：OSPREY BIOPHARMACEUTICALS INC

  公开号：WO2022150726A1

  公开（公告）日：2022-07-14

  The present disclosure provides hypoimmunogenic biotherapeutic compositions that suppress the development of an immune response to themselves in an individual. The present disclosure also provides pharmaceutical compositions that include such hypoimmunogenic biotherapeutics, methods for making such hypoimmunogenic biotherapeutics, and methods for using such hypoimmunogenic biotherapeutics as therapeutics and in research.

  本公开提供了一种低免疫原性生物治疗组合物，可抑制个体对其产生免疫反应。本公开还提供了包含此类低免疫原性生物治疗剂的制药组合物，制备此类低免疫原性生物治疗剂的方法，以及将此类低免疫原性生物治疗剂用作治疗和研究的方法。